Product
Clesrovimab
Aliases
MK-1654
3 clinical trials
3 indications
Indication
Respiratory Syncytial Virus InfectionIndication
Respiratory InfectionIndication
Respiratory Syncytial VirusClinical trial
A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab- Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV DiseaseStatus: Recruiting, Estimated PCD: 2025-06-28
Clinical trial
A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term InfantsStatus: Active (not recruiting), Estimated PCD: 2024-08-15
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term InfantsStatus: Completed, Estimated PCD: 2022-09-14